Prostate Cancer Therapeutics Market to
2019 - Rising Prevalence and Strong Uptake of Recent Approvals to Drive
Robust Growth to 2019”. The recent approval of a number of highly
effective drugs, including Zytiga and Xtandi, has provided late-stage
patients with a number of options and increased survival times by a
number of months. These recent approvals are anticipated to generate
strong revenues during the forecast following increasing uptake by
physicians as the treatment algorithm shifts towards their first-line
usage over Taxotere. Additionally, a very large late-stage pipeline is
anticipated to produce a number of new market entrants which are
superior to existing products. Overall, this is anticipated to drive
rapid market growth from $4.1 billion in 2012 to $8.0 billion by 2019 at
a CAGR of 10.1%.
For More Information Visit: http://www.researchmoz.us/prostate-cancer-therapeutics-market-to-2019-rising-prevalence-and-strong-uptake-of-recent-approvals-to-drive-robust-growth-to-2019-report.html
For More Information Visit: http://www.researchmoz.us/prostate-cancer-therapeutics-market-to-2019-rising-prevalence-and-strong-uptake-of-recent-approvals-to-drive-robust-growth-to-2019-report.html
0 comments:
Post a Comment